Suven to present results from Phase-2a study of Ropanicant at Neuroscience 2024
Suven plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Ropanicant
Suven announces randomisation of first patient in Phase-2 POC clinical trial of Ropanicant…
The Phase-2 clinical trial of Ropanicant (SUVN-911) is for the treatment of moderate to severe Major Depressive Disorder (MDD)…